Wikipedia

Justin Stebbing

Justin Stebbing is a British oncology doctor and cancer researcher. He is a professor of biomedical sciences at Anglia Ruskin University[1] and practices with the private sector Phoenix Hospital Group in London.[2] He specialises in a range of solid malignancies, including difficult cases with few conventional options and has published over 700 papers, the majority regarding therapeutic and translational approaches.[citation needed]

Justin Stebbing

Stebbing is Editor-in-Chief of the journal Oncogene.[3] He is also a visiting professor of cancer medicine and oncology at Imperial College, London [4]

Early life and education edit

Stebbing graduated from Trinity College, Oxford.[citation needed] After completion of junior doctor positions in Oxford, he trained on the residency programme at The Johns Hopkins Hospital in the US, returning to London to continue his career at The Royal Marsden and then St Bartholomew's Hospitals. His PhD research investigated the interplay between the immune system and cancer including the role of viruses.[5][6] In 2007, he was appointed a senior lecturer, and then in 2009 a full professor, at Imperial College London.[7] In 2011, the National Institute for Health and Care Research awarded Stebbing its first Translational Professorship in Oncology, working on overcoming treatment resistance and targeted precision medicine approaches.[8]

Cancer research edit

Stebbing has published over 700 peer-reviewed papers[9] and has an h-index of 89 according to Google Scholar.[10] He is Editor-in-Chief of the journal Oncogene,[11] a Fellow of the Royal College of Physicians,[12] the American Society for Clinical Investigation[13] and the Royal College of Pathologists.[14]

The charity Action Against Cancer was set up to support Stebbing's work.[15] In cancer, some of his most cited papers include the discovery of the role of the oncogene LMTK3 across malignancies, the network of microRNAs induced by the estrogen receptor, and work on HIV and AIDS cancers.[16][17][18][19] He has undertaken extensive work on biosimilars,[20] cheaper versions of expensive biologic drugs designed to democratise access to these.[21]

COVID-19 research edit

During the Covid-19 pandemic in early 2020, Stebbing used artificial intelligence to identify baricitinib as a potential drug treatment.[22][23] He led studies that showed that the drug reduced mortality in COVID-19 hospitalised patients with pneumonia, which led to the drug being authorised by the US Food and Drug Administration in October 2020 as an Emergency Use Authorization at first in combination with remdesivir, then alone.[24] Much of this work is summarized by editorials he wrote in The New England Journal of Medicine and Lancet Respiratory Medicine.[25][26] Stebbing wrote a book, Witness to COVID, 2020 [27][28] describing its discovery, trials, studies and approval.[29] [30] In 2024, he was co-senior author on a paper in Nature Communications[31] using invariant natural killer T cells as an 'off-the-shelf' therapy in ventilated patients with acute respiratory distress syndrome (ARDS), the first time these cells have been used in the clinic.[32]

Misconduct case edit

In 2020, Stebbing was investigated by the General Medical Council over allegations that he failed to provide adequate care to eleven patients he had cared for between 2014 and 2017.[33][34] The case focused on whether Stebbing had prescribed inappropriate courses of treatment in patients whose cancers were too advanced to benefit from the treatment.[35] Following a Medical Practitioners Tribunal Service misconduct hearing, the GMG suspended Stebbing from the UK medical register for nine months in 2022.[36]

Other work edit

Stebbing has worked on neurological therapies for patients with unmet medical needs who are treatment resistant or unresponsive to other existing medications.[37] He has combined his medical career with investing, and he has worked with Atticus Capital, Lansdowne Partners, Vitruvian Partners and Chaired the Board of BB Healthcare Trust.[38] He is senior oncology advisor to Clinical ink[39] and chairs the ZephyrAI scientific advisory board.[40] He is senior VP of clinical strategy and innovation[41] at Graviton Biosciences focusing on new treatments for fibrosis, inflammation and metabolism based on selective targeting of ROCK2.

References edit

  1. ^ "Professor Justin Stebbing - ARU". aru.ac.uk. Retrieved 2022-11-30.
  2. ^ "Professor Justin Stebbing". Phoenix Hospital Group. Retrieved 2022-10-29.
  3. ^ "About the Editors | Oncogene". www.nature.com. Retrieved 2022-10-29.
  4. ^ "Home - Professor Justin Stebbing". www.imperial.ac.uk. Retrieved 2022-10-29.
  5. ^ Stebbing, Justin; Gazzard, Brian; Douek, Daniel C. (2004-04-29). "Where Does HIV Live?". New England Journal of Medicine. 350 (18): 1872–1880. doi:10.1056/NEJMra032395. ISSN 0028-4793. PMID 15115833.
  6. ^ Stebbing, J.; Bower, M. (2003). "Redirecting". The Lancet. Oncology. 4 (7): 438–445. doi:10.1016/S1470-2045(03)01142-2. PMID 12850195. Retrieved 2024-01-07.
  7. ^ "PWP Messages".
  8. ^ "Current NIHR Research Professors". www.nihr.ac.uk. Retrieved 2024-01-07.
  9. ^ "stebbing j - Search Results - PubMed". PubMed. Retrieved 2024-01-07.
  10. ^ "Justin Stebbing". scholar.google.com. Retrieved 2024-01-07.
  11. ^ "About the Editors". Oncogene.
  12. ^ "Home - Professor Justin Stebbing". www.imperial.ac.uk. Retrieved 2024-01-07.
  13. ^ "The American Society for Clinical Investigation".
  14. ^ "Honours and Memberships - Professor Justin Stebbing". www.imperial.ac.uk. Retrieved 2024-01-07.
  15. ^ "Home | Action Against Cancer". www.aacancer.org. Retrieved 28 March 2023.
  16. ^ Giamas, Georgios; Filipović, Aleksandra; Jacob, Jimmy; Messier, Walter; Zhang, Hua; Yang, Dongyun; Zhang, Wu; Shifa, Belul Assefa; Photiou, Andrew; Tralau-Stewart, Cathy; Castellano, Leandro; Green, Andrew R.; Coombes, R. Charles; Ellis, Ian O.; Ali, Simak; Lenz, Heinz-Josef; Stebbing, Justin (June 2011). "Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer". Nature Medicine. 17 (6): 715–719. doi:10.1038/nm.2351. PMID 21602804. S2CID 5279914.[non-primary source needed]
  17. ^ Castellano, Leandro; Giamas, Georgios; Jacob, Jimmy; Coombes, R. Charles; Lucchesi, Walter; Thiruchelvam, Paul; Barton, Geraint; Jiao, Long R.; Wait, Robin; Waxman, Jonathan; Hannon, Gregory J.; Stebbing, Justin (21 August 2009). "The estrogen receptor-α-induced microRNA signature regulates itself and its transcriptional response". Proceedings of the National Academy of Sciences. 106 (37): 15732–15737. Bibcode:2009PNAS..10615732C. doi:10.1073/pnas.0906947106. PMC 2747188. PMID 19706389.[non-primary source needed]
  18. ^ Bower, M.; Nelson, M.; Young, A.M.; Thirlwell, C.; Newsom-Davis, T.; Mandalia, S.; Dhillon, T.; Holmes, P.; Gazzard, B.G.; Stebbing, J. (1 August 2005). "Immune Reconstitution Inflammatory Syndrome Associated With Kaposi's Sarcoma". Journal of Clinical Oncology. 23 (22): 5224–5228. doi:10.1200/JCO.2005.14.597. PMID 16051964.[non-primary source needed]
  19. ^ Stebbing, Justin; Gazzard, Brian; Douek, Daniel C. (29 April 2004). "Where Does HIV Live?". New England Journal of Medicine. 350 (18): 1872–1880. doi:10.1056/NEJMra032395. PMID 15115833.[non-primary source needed]
  20. ^ "Redirecting". linkinghub.elsevier.com. Retrieved 2024-01-07.
  21. ^ Stebbing, Justin; Baranau, Yauheni; Baryash, Valery; Moiseyenko, Vladimir; Boliukh, Dmytro; Antone, Nicoleta; Manikhas, Alexey; Chornobai, Anatolii; Park, Taehong; Baek, Eric Hyungseok; Lee, Jaeyong; Choi, Jiin; Kim, Nahyun; Ahn, Keumyoung; Lee, Sang Joon (2023). "Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial". Biodrugs. 37 (3): 433–440. doi:10.1007/s40259-023-00582-w. ISSN 1173-8804. PMC 10195725. PMID 36881323.
  22. ^ Richardson, Peter; Griffin, Ivan; Tucker, Catherine; Smith, Dan; Oechsle, Olly; Phelan, Anne; Rawling, Michael; Savory, Edward; Stebbing, Justin (15 February 2020). "Baricitinib as potential treatment for 2019-nCoV acute respiratory disease". The Lancet. 395 (10223): e30–e31. doi:10.1016/S0140-6736(20)30304-4. PMC 7137985. PMID 32032529.[non-primary source needed]
  23. ^ "Redirecting". linkinghub.elsevier.com. Retrieved 2024-01-07.
  24. ^ "Olumiant EUA FAQs | FDA". www.fda.gov. Retrieved 2024-02-14.
  25. ^ Stebbing, Justin; Lauschke, Volker M. (2021-07-29). "JAK Inhibitors — More Than Just Glucocorticoids". New England Journal of Medicine. 385 (5): 463–465. doi:10.1056/NEJMe2108667. ISSN 0028-4793. PMC 8362590. PMID 34320294.
  26. ^ Kalil, Andre C; Stebbing, Justin (December 2021). "Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial". The Lancet. Respiratory Medicine. 9 (12): 1349–1351. doi:10.1016/S2213-2600(21)00358-1. ISSN 2213-2600. PMC 8409093. PMID 34480862.
  27. ^ Stebbing, Justin (15 November 2021). Witness to Covid: 2020 | Justin Stebbing | London Review Bookshop. Amberley. ISBN 9781398112674.
  28. ^ Stebbing, Justin (2021-11-15). Witness to Covid: 2020 | Justin Stebbing | London Review Bookshop. Amberley. ISBN 978-1-3981-1267-4.
  29. ^ Witness to Covid: 2020: The Diary of a Global Pandemic: Amazon.co.uk: Stebbing, Justin, Mukherjee, Siddhartha: 9781398112674: Books. ASIN 1398112674.
  30. ^ Metz, Cade (2020-04-30). "How A.I. Steered Doctors Toward a Possible Coronavirus Treatment". The New York Times. ISSN 0362-4331. Retrieved 2024-01-07.
  31. ^ Hammond, Terese C.; Purbhoo, Marco A.; Kadel, Sapana; Ritz, Jerome; Nikiforow, Sarah; Daley, Heather; Shaw, Kit; van Besien, Koen; Gomez-Arteaga, Alexandra; Stevens, Don; Ortuzar, Waldo; Michelet, Xavier; Smith, Rachel; Moskowitz, Darrian; Masakayan, Reed (2024-02-06). "A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome". Nature Communications. 15 (1): 974. Bibcode:2024NatCo..15..974H. doi:10.1038/s41467-024-44905-z. ISSN 2041-1723. PMC 10847411. PMID 38321023.
  32. ^ Reporters, Telegraph (2024-02-07). "New cancer drug could improve prognosis for Covid patients". The Telegraph. ISSN 0307-1235. Retrieved 2024-02-14.
  33. ^ Dyer, Clare (2020-09-15). "Leading oncologist faces GMC allegations of inappropriate treatment of dying patients". BMJ. 370: m3594. doi:10.1136/bmj.m3594. ISSN 1756-1833. PMID 32933903.
  34. ^ "Leading Oncologist Guilty of Providing Inappropriate Treatment: MPTS". Medscape UK. Retrieved 2022-05-25.
  35. ^ ""Saviour or Sinner?" Why the case of Justin Stebbing matters". 13 November 2022.
  36. ^ Dyer, Clare (2021-12-21). "Oncologist with "cavalier attitude" to treatment is suspended for nine months after patients defend his practice". BMJ. 375: n3130. doi:10.1136/bmj.n3130. ISSN 1756-1833. PMID 34933876.
  37. ^ Corp, Equilibre Biopharmaceuticals. "Equilibre Biopharmaceuticals Announces Positive Topline Results from Phase 2 Clinical Trial of EQU-001 (NCT05063877) for Safety, Tolerability and Preliminary Efficacy as Adjunctive Therapy for Focal Seizures in Adults with Epilepsy". www.prnewswire.com (Press release). Retrieved 2024-01-07.
  38. ^ "BB Healthcare Trust delivers as it comfortably beats its benchmark". Proactiveinvestors UK. 2018-02-14. Retrieved 2024-01-07.
  39. ^ "Justin Stebbing, PhD, M.D. | Expert Advisor". Clinical ink. Retrieved 2024-01-07.
  40. ^ "Zephyr AI Announces Formation of Scientific and Medical Advisory Board". www.businesswire.com. 2022-12-05. Retrieved 2024-01-07.
  41. ^ "Our Company". gravitoncorp.com. Retrieved 2024-02-14.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Justin_Stebbing&oldid=1224938559"